Exchange: NASDAQ Capital Market Sector: Financial Services Industry: Shell Companies
2.48% $9.50
/ 22 nov 2022 @ 15:59
RATING 2022-11-22 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 61.29 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 61.29 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 9.41 - 9.59 ( +/- 0.96%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-22 | Viking Global Investors Lp | Sell | 1 211 582 | Class A Ordinary Shares |
2022-11-22 | Topper David Joseph | Sell | 30 000 | Class B Ordinary Shares |
2022-11-22 | Bigham Michael | Sell | 30 000 | Class B Ordinary Shares |
2022-11-22 | Polu Krishna R | Sell | 30 000 | Class B Ordinary Shares |
2022-11-22 | Baltera Robert Jr. | Sell | 30 000 | Class B Ordinary Shares |
INSIDER POWER |
---|
-27.56 |
Last 23 transactions |
Buy: 2 848 395 | Sell: 8 361 582 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $9.50 (2.48% ) |
Volume | 0.0182 mill |
Avg. Vol. | 0.0045 mill |
% of Avg. Vol | 405.10 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.